Domain Therapeutics NA (DTNA) Inc. specializes in G Protein-Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) signaling and function.
Our BRET-based bioSensAllTM biosensor technology allows for detailed and broad-spectrum signaling profiling of GPCRs, RTKs and their ligands, while leaving these receptors untagged. This technology revolves primarily around the real-time monitoring of receptor proximal events immediately linked to the transmembrane receptor activity, namely heterotrimeric G protein activation and β-arrestin coupling for the GPCRs, and SH2-domain proteins for the RTKs.

The GPCR assay brings the unique capacity to quantify the engagement of 14 distinct heterotrimeric G protein subtypes as well as both non-visual β-arrestin isoforms.
The RTK assay gives the possibility to follow the recruitment of various SH2-domain proteins and study the complete trafficking of these receptors.
Both assays provide a complete and detailed fingerprint of any GPCR / RTK ligand and allow to study the impact of receptor mutations on their signaling. This data is particularly valuable in a screen / early drug development program to select and optimally design your lead compound.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

validation of its technologies through collaborative partnerships with Pharma/Biotechs,
generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.